Elite Pharmaceuticals, Inc. specializes in the development

New Post Public Reply Private Reply Replies (0) Message Board
Stock Buff

Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders.  The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products, using proprietary technology and the development and manufacture of generic pharmaceuticals. The company focuses on development of its pain management products; manufacturing of a line of generic pharmaceutical products with approved Abbreviated New Drug Application; development of additional generic pharmaceutical products; development of the other products in its pipeline; commercial exploitation of its products either by license and the collection of royalties, or through the manufacture of its formulations; and development of new products and the expansion of its licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures, and other collaborations. The company has four products, including Phentermine 37.5mg tablets; Methadone 10mg tablets; Lodrane D Immediate Release capsules; and Hydromorphone Hydrochloride 8mg tablets. The company has license agreement with Precision Dose Inc. to market and sell four Elite generic products, consisting of Hydromorphone, Naltrexone, Phentermine 37.5mg tablets (Phentermine 37.5mg) and one additional generic products. The company has a pipeline of additional generic drug candidates under active development, including, without limitation, ELI-154, a once-a-day oxycodone product and ELI-216, an abuse resistant oxycodone product which utilizes its propriety formulation for abuse resistant products utilizing the pharmacological approach (Elite’s Abuse Resistant Technology). Products under Development ELI-154 and ELI-216 For ELI-154, the company has developed a once-daily oxycodone formulation using its proprietary technology. An investigational new drug application (IND) has been filed and Elite has completed two pharmacokinetic studies in healthy subjects that compared blood levels of oxycodone from dosing ELI-154 and the twice-a-day product that is on the market, OxyContin marketed in the U.S. by Purdue Pharma LP. ELI-216 utilizes the company’s patent-pending abuse-deterrent technology that is based on a pharmacological approach. ELI-216 is a combination of a narcotic agonist, oxycodone hydrochloride, in a sustained-release formulation intended for use in patients with moderate to severe chronic pain, and an antagonist, naltrexone hydrochloride, formulated to deter abuse of the drug. The company has developed ELI-154 and ELI-216 and retains the rights to these products. Strategic Alliance Agreement The company and Epic Pharma, LLC and Epic Investments, LLC, a subsidiary of Epic Pharma LLC (collectively, Epic) entered into the Epic Strategic Alliance Agreement. Epic is a pharmaceutical company that operates a business synergistic to that of Elite in the research and development, manufacturing, and sales and marketing of oral immediate release and controlled-release drug products. Research and Development As of March 31, 2012, the company spent $1,735,689 on research and development activities. Commercial Products In 2011, the company commenced shipping phentermine HCl 37.5 mg tablets to TAGI Pharma Inc. Phentermine tablets are a commercial product being distributed by its partner, TAGI Pharma Inc. In 2011, the company made the initial shipment of Lodrane D immediate release capsules to ECR Pharmaceuticals. Lodrane D is an immediate release formulation of brompheniramine maleate and pseudoephedrine HCl. In January 2012, the company commenced shipping Methadone 10mg tablets to ThePharmaNetwork, LLC and its wholly owned subsidiary, Ascend Laboratories, LLC. pursuant to a commercial manufacturing and supply agreement. In March 2012, the company commenced shipping Hydromorphone 8mg to TAGI Pharma Inc. Strategy The company’s strategy includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products with high barriers to entry. Significant Events In April 2011, the company ceased production of the Lodrane Extended Release Products, which are the subject of the agreements with ECR Pharmaceuticals, pursuant to the FDA’s announcement of its intention to remove approximately 500 cough/cold and allergy related products from the U.S. market, including the Lodrane Extended Release Products. History Elite Pharmaceuticals, Inc. was founded in 1984. The company was incorporated in 1997 under the laws of the state of Delaware. In 2012, the company was reincorporated under the laws of the state of Nevada.

Elite Pharmaceuticals, Inc. Announces First Shipment of Generic Phentermine Capsules
NORTHVALE, Apr 11, 2013 (GLOBE NEWSWIRE via COMTEX) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the initial shipment of phentermine HCl capsules 15 mg and 30 mg under the License, Manufacturing and Supply Agreement with its sales and marketing partner, triggering a milestone payment. Elite's sales and marketing partner will distribute the product as part of a multi-product distribution agreement.

Phentermine is a member of the bariatric class of drugs intended to aid in weight loss. For the twelve months ending December 31, 2012, Adipex-P(R) 15 mg and 30 mg and its generic equivalents had total U.S. sales of approximately $2.5 million and $5 million respectively according to IMS Health Data. U.S. sales of this product are thought to be greater than the IMS data due to its distribution through channels that are not included in IMS data.

"Elite has successfully launched another product line, this one encompassing two dose strengths. Management remains dedicated to enhancing shareholder value by expanding our generic portfolio of products, continuing the development of our abuse-resistant opioid line of products, enhancing our intellectual property, and strengthening the balance sheet," commented Jerry Treppel, Elite's Chairman and CEO.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has five commercial products currently being sold, an additional product approved and soon to be launched, and one additional product pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Actavis and Ascend Laboratories (previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.

 CONTACT: For Elite Pharmaceuticals, Inc.
         Dianne Will, Investor Relations, 518-398-6222
         Dianne@elitepharma.com
          www.elitepharma.com  
 
http://media.globenewswire.com/cache/9233/small/9551.jpg

http://www.globenewswire.com/newsroom/ti?nf=M...IjOTIzMw==

 (C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.
 
-0-
 KEYWORD:          NORTHVALE
INDUSTRY KEYWORD: Drugs
SUBJECT CODE:     Company Announcement
                  PHARMACEUTICALS
 

Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 46

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Cruise Line Celebrates Employees as Godparents of Treasure

Updated Category News Views 97

Disney Cruise Line Celebrates Employees in Honor of Disney Treasure Disney Cruise Line is redefining maritime traditions in a beautiful manner by honoring its dedicated employees worldwide. The company’s latest announcement revealed that the honorific role of "godparent" for the new ship, the Disney Treasure, will be shared among its tremendous cast, crew, Imagineers,...

Continue Reading
Regional Management Corp. to Share Q3 2024 Financial Insights

Updated Category News Views 79

Regional Management Corp. to Announce Q3 Results Greenville, S.C. – Regional Management Corp. (NYSE: RM), a prominent player in the consumer finance sector, is set to share its financial results for the third quarter of 2024. Conference Call Details and Replay The company will report its quarterly results after market close, providing investors and stakeholders with...

Continue Reading
Suvoda Recognized as a Leader in Clinical Trial Technology

Updated Category News Views 147

Suvoda Acknowledged as a Leader in RTSM Technology Suvoda, a cutting-edge clinical trial technology company, recently shared exciting news about their IRT (Interactive Response Technology) software, which has been designated as a Leader in the prominent Everest Group's PEAK Matrix assessment for RTSM (Randomization and Trial Supply Management) technology. This recognition...

Continue Reading
Cereno Scientific Expands CS014 Focus to Combat PH-ILD

Updated Category News Views 131

Cereno Scientific Expands CS014 Focus to Combat PH-ILD Cereno Scientific, a pioneering biotech company, has made a significant announcement regarding the development focus of its HDAC inhibitor CS014. This innovative treatment is now targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), an area marked by a high level of unmet medical need....

Continue Reading
Dysmenorrhea Treatment Market Growth Insights for 2032

Updated Category News Views 188

Global Dysmenorrhea Treatment Market Insights Dysmenorrhea, commonly referred to as menstrual cramps, affects many women globally, causing significant discomfort during their menstrual cycles. Recent trends indicate that as awareness of this condition grows, so does the demand for effective treatments. The global dysmenorrhea treatment market is projected to surpass USD 8...

Continue Reading